Abstract
The concentration of magnesium in serum has been shown to fall to potentially dangerously low levels after several courses of treatment with cis-diamminedichloroplatinum II (cis-platin). The aims of this study were to examine the effects of magnesium supplementation on predicted outcome of treatment, rate of response to treatment and toxicity of treatment. Sixteen patients with testicular cancer were studied in detail over a 14 month period. One patient with an ovarian dysgerminoma was also included in the study. Eight patients were randomised to receive magnesium supplements both intravenous and oral; nine did not. The non-supplemented group showed significantly greater renal tubular damage as assessed by urine N-acetyl-B-D-glucosaminidase (NAG). There was a trend towards a reduction in treatment delays due to neutropenic episodes in the supplemented group, and serum magnesium concentrations remained significantly higher. Neither group showed differences in tumour growth rates or outcome. These results show that magnesium supplements are of considerable benefit and show no harmful effects in patients receiving cis-platin treatment. It is is suggested that magnesium supplements should be a routine part of the treatment regime, and that these should comprise both i.v. supplements during treatment and oral supplements between courses.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
- Macaulay V. M., Begent R. H., Phillips M. E., Newlands E. S. Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy. Cancer Chemother Pharmacol. 1982;9(3):179–181. doi: 10.1007/BF00257749. [DOI] [PubMed] [Google Scholar]
- Ohnuma T., Holland J. F. Nutritional consequences of cancer chemotherapy and immunotherapy. Cancer Res. 1977 Jul;37(7 Pt 2):2395–2406. [PubMed] [Google Scholar]
- Parsons F. M., Edwards G. F., Anderson C. K., Ahmad S., Clark P. B., Hetherington C., Young G. A. Regression of malignant tumours in magnesium and potassium depletion induced by diet and haemodialysis. Lancet. 1974 Feb 16;1(7851):243–244. doi: 10.1016/s0140-6736(74)92549-5. [DOI] [PubMed] [Google Scholar]
- Schilsky R. L., Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun;90(6):929–931. doi: 10.7326/0003-4819-90-6-929. [DOI] [PubMed] [Google Scholar]
- Schilsky R. L., Barlock A., Ozols R. F. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep. 1982 Sep;66(9):1767–1769. [PubMed] [Google Scholar]
- Stuart-Harris R., Ponder B. A., Wrigley P. F. Tetany associated with cis-platin. Lancet. 1980 Dec 13;2(8207):1303–1303. doi: 10.1016/s0140-6736(80)92367-3. [DOI] [PubMed] [Google Scholar]
- Wacker W. E., Parisi A. F. Magnesium metabolism. N Engl J Med. 1968 Apr 4;278(14):772–concl. doi: 10.1056/NEJM196804042781406. [DOI] [PubMed] [Google Scholar]
- Willox J. C., Corr J., Shaw J., Richardson M., Calman K. C., Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984 Jan 7;288(6410):27–27. doi: 10.1136/bmj.288.6410.27. [DOI] [PMC free article] [PubMed] [Google Scholar]